Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on September 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $400M five-year senior secured facility, with $75M drawn at closing for working capital and general corporate purposes.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $400M five-year senior secured facility, with $75M drawn at closing for working capital and general corporate purposes
- Additional borrowing tied to FDA BLA approval, lonvo-z revenue targets, and a $30M equity fundraising target
- Loans mature September 4, 2031, with monthly interest at one-month SOFR plus 6.15%, subject to a 3.00% floor
- First-priority collateral includes substantially all company assets, including intellectual property
- $50M minimum liquidity covenant before lonvo-z BLA approval, alongside restrictions on debt, acquisitions, licensing, and asset sales
Item 2.03 · Creation of a Direct Financial Obligation
- Intellia secured a non-dilutive debt facility with OrbiMed for up to $400 million
- Financing creates borrowing capacity without immediate equity dilution
- Press release provides facility terms, including interest rate, maturity, and draw conditions
Item 7.01 · Regulation FD Disclosure
- Forward-looking disclosure centers on Credit Facility proceeds, milestone-based draws, and potential additional $100 million subject to lender agreement
- Additional borrowing depends on regulatory, revenue, and equity-financing milestones, creating execution and liquidity risk
- Potential lonvoguran ziclumeran approval for hereditary angioedema remains uncertain and material to Intellia’s strategy
- Market conditions and SEC-documented risks could materially alter financing access and development outcomes
Item EX-99.1 · Exhibit EX-99.1
- $75 million funded upfront under a $400 million non-dilutive senior secured term loan
- Additional $225 million available through five milestone-based tranches, primarily tied to lonvo-z
- Potential $100 million more available by mutual agreement during the five-year term
- Financing supports lonvo-z launch preparations and nex-z development without immediate equity dilution
- Senior secured debt adds repayment obligations, restrictive covenants, security interests, and default risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.